The hedgehog pathway inhibitors market is expected to grow by USD 328.39 million during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the hedgehog pathway inhibitors market in optimistic, probable, and pessimistic forecast scenarios.
The hedgehog pathway inhibitors market will witness a neutral impact during the forecast period owing to the widespread growth of the COVID-19 pandemic. As per Technavio's pandemic-focused market research, market growth is likely to increase in 2021 as compared to 2020.
With the continuing spread of the coronavirus pandemic, organizations across the globe are gradually flattening their recessionary curve by leveraging technology. Many businesses will go through response, recovery, and renewal phases. Building business resilience and enabling agility will aid organizations to move forward in their journey out of the COVID-19 crisis towards the Next Normal.
Key Considerations for Market Forecast:
Impact of lockdowns, supply chain disruptions, demand destruction, and change in customer behavior
Optimistic, probable, and pessimistic scenarios for all markets as the impact of pandemic unfolds
Pre- as well as post-COVID-19 market estimates
Quarterly impact analysis and updates on market estimates
The hedgehog pathway inhibitors market is driven by the high-risk factors for BCC and AML. In addition, the increasing awareness about BCC and AML are expected to trigger the hedgehog pathway inhibitors market toward witnessing a CAGR of almost 13% during the forecast period.
Major Five Hedgehog Pathway Inhibitors Market Participants:
F. Hoffmann-La Roche Ltd.: The company offers Erivedge which is used for the treatment of adults with metastatic BCC or with locally advanced BCC. The recommended dose is one daily oral dose of 150 mg.
Inhibitor Therapeutics Inc.: The company offers SUBA-Itraconazole which is a patented formulation of itraconazole developed by Mayne Pharma, which is designed to improve the bioavailability of orally administered drugs that are poorly soluble.
MAX BioPharma Inc.: The company offers Oxysterols that are oxidized derivatives of cholesterol that can be activators or inhibitors of specific cellular signaling pathways, including Hedgehog and TGF pathways.
Mayne Pharma Group Ltd.: The company offers TOLSURA (SUBA-itraconazole) Capsules which is an azole antifungal indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised adult patients.
PellePharm Inc.: Patidegib is the key product of the company. It is under development for the treatment of BCC.
Hedgehog pathway inhibitors market is segmented as below:
Related Report on Healthcare Include:
Global Stem Cell Therapy Market - The global stem cell therapy market report identifies the increase in awareness of stem cell therapy as one of the primary drivers. Know about other driving factors and statistics related to the market. View Statistics Data Here
About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.